Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)

Mylan logo

Mylan

Status and phase

Completed
Phase 3

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Treatments

Drug: Placebo
Drug: TD-4208

Study type

Interventional

Funder types

Industry

Identifiers

NCT02459080
0126

Details and patient eligibility

About

The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.

Enrollment

619 patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject is a male or female subject 40 years of age or older

Exclusion criteria

Females who are pregnant, lactating, breast-feeding or planning to become pregnant during the study

Trial design

619 participants in 3 patient groups, including a placebo group

TD-4208-1
Active Comparator group
Description:
88 mcg
Treatment:
Drug: TD-4208
TD-4208-2
Active Comparator group
Description:
175 mcg
Treatment:
Drug: TD-4208
Placebo
Placebo Comparator group
Description:
Placebo
Treatment:
Drug: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems